Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-127275
Filing Date
2024-11-14
Accepted
2024-11-14 18:01:09
Documents
2
Period of Report
2024-11-12

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 18275
2 EX-24.1 - POWER OF ATTORNEY itci-ex24_1.htm EX-24.1 11346
  Complete submission text file 0000950170-24-127275.txt   31192
Mailing Address C/O INTRA-CELLULAR THERAPIES, INC. 135 ROUTE 202/206 BEDMINSTER NJ 07921
Business Address
Halstead Michael (Reporting) CIK: 0001521548 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36274 | Film No.: 241464860

Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Issuer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)